BioCentury | Feb 23, 2021
Product Development

FDA’s Marks says time is now to start trials for vaccines against new COVID-19 variants as agency issues guidance

...monoclonal antibody products to address this unmet medical need.”...
BioCentury | Feb 6, 2021
Product Development

Incyte continues layering on new opportunities

...it just happened that the biology told us there was this autoimmune disease, a large medical need...
BioCentury | Jan 29, 2021
Politics, Policy & Law

What we must do to prepare for the next pandemic, a guest commentary

...to continue for as long as the medical need...
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

Saying goodbye to a grueling year, BioCentury editors have furrowed among the disasters to pick out some of the positives from 2020, and call out some of the worst of the pandemic’s collateral damage....
BioCentury | Dec 31, 2020
Product Development

Stoffels on how J&J designed its COVID-19 vaccine for maximum impact: a BioCentury audio interview

...vaccine in the world with Moderna and with Pfizer. We will cater to the highest medical need...
...according to their principles. They do 5%, 10%, 20%, they also look at the highest medical need...
...see now in Europe, we see it in the U.S., you start with the highest medical need...
BioCentury | Dec 11, 2020
Product Development

CAR Ts make the move to earlier lines of treatment despite access barriers

...knowing there is also a high unmet medical need...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...opportunity, clinically de-risked and addresses an unmet medical need...
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...
BioCentury | Sep 11, 2020
Product Development

Hamburg on how COVID-19 collaboration models could propel drug development for public health priorities: a BioCentury audio interview

The extraordinary collaboration and commitment on the part of biopharma companies and governments that COVID-19 has inspired should serve as models for addressing unmet medical needs after the crisis has passed, Margaret Hamburg, who served...
BioCentury | Sep 1, 2020
Product Development

Disease setting shields Vir, GSK trial of COVID-19 mAb from plasma EUA

...Antibody Pack”)In choosing the narrower population, Pang said, “Our thought was: let’s go where the medical need...
Items per page:
1 - 10 of 373
BioCentury | Feb 23, 2021
Product Development

FDA’s Marks says time is now to start trials for vaccines against new COVID-19 variants as agency issues guidance

...monoclonal antibody products to address this unmet medical need.”...
BioCentury | Feb 6, 2021
Product Development

Incyte continues layering on new opportunities

...it just happened that the biology told us there was this autoimmune disease, a large medical need...
BioCentury | Jan 29, 2021
Politics, Policy & Law

What we must do to prepare for the next pandemic, a guest commentary

...to continue for as long as the medical need...
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

Saying goodbye to a grueling year, BioCentury editors have furrowed among the disasters to pick out some of the positives from 2020, and call out some of the worst of the pandemic’s collateral damage....
BioCentury | Dec 31, 2020
Product Development

Stoffels on how J&J designed its COVID-19 vaccine for maximum impact: a BioCentury audio interview

...vaccine in the world with Moderna and with Pfizer. We will cater to the highest medical need...
...according to their principles. They do 5%, 10%, 20%, they also look at the highest medical need...
...see now in Europe, we see it in the U.S., you start with the highest medical need...
BioCentury | Dec 11, 2020
Product Development

CAR Ts make the move to earlier lines of treatment despite access barriers

...knowing there is also a high unmet medical need...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...opportunity, clinically de-risked and addresses an unmet medical need...
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...
BioCentury | Sep 11, 2020
Product Development

Hamburg on how COVID-19 collaboration models could propel drug development for public health priorities: a BioCentury audio interview

The extraordinary collaboration and commitment on the part of biopharma companies and governments that COVID-19 has inspired should serve as models for addressing unmet medical needs after the crisis has passed, Margaret Hamburg, who served...
BioCentury | Sep 1, 2020
Product Development

Disease setting shields Vir, GSK trial of COVID-19 mAb from plasma EUA

...Antibody Pack”)In choosing the narrower population, Pang said, “Our thought was: let’s go where the medical need...
Items per page:
1 - 10 of 373